Charles River Laboratories Given Consensus Recommendation of “Hold” by Analysts (NYSE:CRL)
Charles River Laboratories (NYSE:CRL) has been given an average recommendation of “Hold” by the thirteen analysts that are covering the company, Stock Ratings Network.com reports. Eight research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $58.00.
In other Charles River Laboratories news, CFO Thomas F. Ackerman sold 23,156 shares of the company’s stock on the open market in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $59.25, for a total value of $1,371,993.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Several analysts have recently commented on the stock. Analysts at Deutsche Bank reiterated a “hold” rating on shares of Charles River Laboratories in a research note on Wednesday, August 13th. They now have a $59.00 price target on the stock, up previously from $58.00. Separately, analysts at Credit Suisse reiterated a “neutral” rating on shares of Charles River Laboratories in a research note on Friday, August 8th. They now have a $60.00 price target on the stock, up previously from $56.00. Finally, analysts at SunTrust initiated coverage on shares of Charles River Laboratories in a research note on Tuesday, June 24th. They set a “neutral” rating and a $55.00 price target on the stock.
Charles River Laboratories (NYSE:CRL) opened at 60.45 on Wednesday. Charles River Laboratories has a 52-week low of $44.12 and a 52-week high of $62.50. The stock has a 50-day moving average of $55.5 and a 200-day moving average of $56.16. The company has a market cap of $2.822 billion and a price-to-earnings ratio of 24.72.
Charles River Laboratories (NYSE:CRL) last released its earnings data on Wednesday, August 6th. The company reported $0.97 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.82 by $0.15. The company had revenue of $341.18 million for the quarter, compared to the consensus estimate of $327.96 million. During the same quarter last year, the company posted $0.73 earnings per share. Charles River Laboratories’s revenue was up 16.5% compared to the same quarter last year. On average, analysts predict that Charles River Laboratories will post $3.33 earnings per share for the current fiscal year.
Charles River Laboratories International, Inc is a global provider of solutions, which accelerate the early-stage drug discovery and development process.
Receive News & Ratings for Charles River Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories and related companies with Analyst Ratings Network's FREE daily email newsletter.